SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Jackie Robinson

PatientJackie Robinson
Date of birth1974-01-31
IdentifiersMRN HR-ML037-SYN; SSN (made up) 000-37-2286
Document date2026-10-26
AuthorMarcus Delacroix-Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist. [S]

History of Present Illness

Mr. Robinson returns three months after his first visit. He had the third injections in both eyes a month ago and laser treatment to the right eye nearly three weeks ago. Dr. Ostrowski-Lane reports that the blood has largely cleared, the new vessels are regressing, the macular swelling is much less (central subfield 318 microns right and 334 left at the last scan), and his acuity has improved to 52 letters right and 68 left; she judges the retina stable enough to start a GLP-1 receptor agonist at a low dose with monthly review. The low-vision visit gave him magnifiers and better lighting. He walks two and a half blocks before calf pain in the exercise program. No chest pain. No low blood sugar. His PSA, HIV and hepatitis C tests were normal. He says the counseling helps and he sleeps better, though the loss is with him every day. [S]

ElementDetail
EyesThree injections both eyes and laser right eye; acuity 52 and 68 letters
WalkingTwo and a half blocks
ScreeningPSA, HIV and hepatitis C normal
MoodPHQ-9 6

Review of Systems

SystemResultFinding
EyesPositiveVision clearer; reads large print with a magnifier
CardiovascularPositiveCalf pain after two and a half blocks; no chest pain
EndocrineNegativeNo low blood sugar
GastrointestinalNegativeNo nausea or change in bowel habit
PsychiatricPositiveGrieving; sleeping better

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route2025-03-03activeS
Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70At bedtime, by the gradual titration planSubcutaneous route2025-03-03activeS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03 to 2026-07-29completedS
Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake)One tablet dailyOral route2026-07-27activeS
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03activeS
Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutesAs needed for severe low blood sugarNasal route2026-07-27activeS
Metoprolol succinate extended-release 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-08-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the firstAs needed for chest pain, up to three dosesSublingual route2026-08-12activeS
Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route2026-07-29activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparationOne tablet daily, with sick-day rulesOral route2026-07-29activeS
Ezetimibe 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-10-26activeS
Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stableOnce a week, same day each weekSubcutaneous route2026-10-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height180cmS
2026-10-26Body weight101.4kgS
2026-10-26Body mass index (BMI) [Ratio]31.3kg/m2S
2026-10-26Systolic blood pressure126mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate60/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Hemoglobin A1c/Hemoglobin.total in Blood9.2%Below 5.7% is normal; his first goal below 8%, then below 7%, lowered graduallyHighS
2026-10-26Albumin/Creatinine [Mass Ratio] in Urine54mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2)HighS
2026-10-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-10-26Cholesterol [Mass/volume] in Serum or Plasma150mg/dL<=199 mg/dLNormalS
2026-10-26Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation74mg/dLGoal below 55 mg/dL with atherosclerotic diseaseNormalS
2026-10-26Cholesterol in HDL [Mass/volume] in Serum or Plasma40mg/dL>=40 mg/dLNormalS
2026-10-26Triglyceride [Mass/volume] in Serum or Plasma180mg/dL<=149 mg/dLHighS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/76, pulse 60; weight 101.4 kg
CardiovascularRegular rhythm; no ankle swelling
FeetHeel healed; no new breaks; fitted shoes
PsychiatricComposed; no thoughts of self-harm

Problems

ProblemClinical statusVerificationCodeProvenance
Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arrangedresolvedconfirmed H53.8S — Synthetic presenting finding, superseded by the retinal diagnosis two days later.
Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arrangedresolvedconfirmed R07.89S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test.
Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%)activeconfirmed E11.65S — Synthetic modern episode linked to his documented diabetes.
Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters leftactiveconfirmed E11.3513S — Synthetic retinal findings anchored to his documented loss of vision.
Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasoundactiveconfirmed H43.11S — Synthetic finding.
Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg)activeconfirmed I12.9S — Synthetic modern episode linked to his documented high blood pressure.
Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79activeconfirmed E11.22S — Synthetic kidney findings.
Chronic kidney disease G2 A2activeconfirmed N18.2S — Synthetic kidney finding.
Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulsesactiveconfirmed E11.51S — Synthetic modern episode linked to the documented artery damage in his legs.
Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testingactiveconfirmed E11.42S — Synthetic modern episode linked to the documented nerve damage in his legs.
History of two mild strokes a year ago, without lasting weaknessactiveconfirmed Z86.73S — Synthetic modern coding of the documented strokes.
Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dLactiveconfirmed E78.5S — Synthetic laboratory finding.
Bereavement: his eldest son died in a car crash six weeks agoactiveconfirmed Z63.4S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder.
Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiologyactiveconfirmed I25.119S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode.
Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery diseaseresolvedconfirmed S90.821AS — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (seated, two readings, large cuff)Every visitCompleted today126/76
ExaminationWeight and BMIEvery visitCompleted today101.4 kg, down 2.6 kg
LaboratoryHemoglobin A1cEvery 3 months while not at goal or after a changeCompleted today9.2%, from 10.4%
LaboratoryUrine albumin-to-creatinine ratioThree to six months after a treatment change; then 1 to 4 times a year by riskCompleted today54 mg/g, from 86
LaboratoryPotassium, creatinine and eGFRTwo to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 monthsCompleted todaySodium 139, potassium 4.7 mmol/L; creatinine 1.18 mg/dL; eGFR 74
LaboratoryLipid panel4 to 12 weeks after starting or changing a statin; then yearlyDeferredLate: the panel due 4 to 12 weeks after the atorvastatin increase was not ordered at the four-week visit and was drawn today, at thirteen weeks. No harm: LDL 74 mg/dL, total cholesterol 150, HDL 40, triglycerides 180 mg/dL; ALT 30 U/L. Corrective action: follow-up lipids for today's ezetimibe booked before he left, at four to eight weeks
ImagingRetina care: acuity, OCT, injections and laserMonthly at the retina clinic while treatingCompleted todayRetina report reviewed: third injections and right-eye laser done; central subfield 318 and 334 microns; acuity 52 and 68 letters; monthly review continues
Medication safetyRetinopathy safety with a GLP-1 receptor agonistRetina review within a month of starting and before each dose increaseCompleted todayStarted only with the retina specialist's agreement; lowest dose; monthly review booked
ImagingAnkle-brachial indexAt diagnosis of peripheral artery disease; then with any change in symptoms or a woundNot indicatedNo change in symptoms and no wound; repeat only if symptoms change
ExaminationFoot inspection; comprehensive foot examinationEvery visit with loss of sensation; comprehensive examination yearlyCompleted todayHeel healed; no new breaks
ExaminationAngina reviewEvery visitCompleted todayNo angina on metoprolol
SurveyDepression screen (PHQ-9)At intake and at three months while grieving; at least yearlyCompleted todayPHQ-9 6, item 9 scored 0
LaboratoryVitamin B12 on metforminPeriodically on long-term metforminUp to date380 pg/mL at intake
Medication safetyMedicine safety: low blood sugar, sick-day rules, genital infection, dizziness, costEvery visitCompleted todayNo low blood sugar; sick-day rules reviewed for the colonoscopy preparation
Medication safetyCOVID-19 and hepatitis B vaccinesCOVID-19 each autumn; hepatitis B for adults with diabetes under 60Completed todayBoth given; hepatitis B dose 2 in one month; zoster dose 2 due
Self-managementLow-vision services and diabetes tools he can useWhen vision limits daily lifeCompleted todayLow-vision evaluation done: magnifiers, lighting and voice tools

Goal progress:

Immunizations given today: COVID-19 vaccine, mRNA, this season; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]

Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023)

Follow-up: Retina clinic monthly. Lipids in four to eight weeks. Hepatitis B dose 2 in one month. Colonoscopy next month with the written preparation plan. Review in three months with the A1c. Call for nausea or vomiting that stops him drinking, any change in vision, chest pain, or a skin break on the feet. [S]